Paramita Chakraborty
Overview
Explore the profile of Paramita Chakraborty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
649
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oberholtzer N, Chakraborty P, Kassir M, Dressman J, Das S, Mills S, et al.
Sci Adv
. 2024 Nov;
10(46):eadp1152.
PMID: 39546607
The role of tumor microenvironment (TME)-associated inadequate protein modification and trafficking due to insufficiency in Golgi function, leading to Golgi stress, in the regulation of T cell function is largely...
2.
Oberholtzer N, Mills S, Mehta S, Chakraborty P, Mehrotra S
Adv Cancer Res
. 2024 Jul;
162:99-124.
PMID: 39069371
It has been well established that in addition to oxygen's vital in cellular respiration, a disruption of oxygen balance can lead to increased stress and oxidative injury. Similarly, reduced oxygen...
3.
Wofford W, Kim J, Kim D, Janneh A, Lee H, Atilgan F, et al.
Cell Rep
. 2024 Jul;
43(8):114532.
PMID: 39046874
Programmed death ligand 1, PD-L1 (CD274), facilitates immune evasion and exerts pro-survival functions in cancer cells. Here, we report a mechanism whereby internalization of PD-L1 in response to alterations of...
4.
Klinzing K, Das S, Chakraborty P
J Leukoc Biol
. 2024 Jun;
116(3):437-439.
PMID: 38856163
No abstract available.
5.
Majumder M, Janakiraman H, Chakraborty P, Vijayakumar A, Mayhue S, Yu H, et al.
Oral Oncol Rep
. 2024 Apr;
10.
PMID: 38681116
Hu Antigen R, also known as ELAVL1 (HuR), is a key posttranscriptional regulator in eukaryotic cells. HuR overexpression promotes several malignancies, including head and neck squamous cell carcinoma (HNSCC). However,...
6.
Kar A, Ghosh P, Gautam A, Chowdhury S, Basak D, Sarkar I, et al.
Proc Natl Acad Sci U S A
. 2024 Mar;
121(11):e2315989121.
PMID: 38451948
PD1 blockade therapy, harnessing the cytotoxic potential of CD8 T cells, has yielded clinical success in treating malignancies. However, its efficacy is often limited due to the progressive differentiation of...
7.
Chakraborty P, Mills S, Mehrotra S
Cancer Res
. 2023 Oct;
83(20):3321-3323.
PMID: 37828860
Tissue-resident memory T cells (Trm) represent a diverse cell type with tissue-specific gene signatures that can operate as both effector and memory T cells. Trm cells play a crucial role...
8.
Zhang J, Ye Z, Chakraborty P, Luo Z, Culpepper J, Aslam M, et al.
Pharmacol Res
. 2023 Aug;
196:106899.
PMID: 37648102
While recent targeted and immunotherapies in malignant melanoma are encouraging, most patients acquire resistance, implicating a need to identify additional drug targets to improve outcomes. Recently, attention has been given...
9.
Zhang J, Ye Z, Brautigam L, Chakraborty P, Luo Z, Culpepper J, et al.
J Biol Chem
. 2023 Jun;
299(8):104920.
PMID: 37321450
Recent advancements in the treatment of melanoma are encouraging, but there remains a need to identify additional therapeutic targets. We identify a role for microsomal glutathione transferase 1 (MGST1) in...
10.
Kang I, Baliga U, Chatterjee S, Chakraborty P, Choi S, Buchweitz N, et al.
iScience
. 2022 Aug;
25(9):104818.
PMID: 36034228
Osteogenesis imperfecta (OI) is characterized by repeated bone fractures. Recent studies have shown that T lymphocytes and regulatory T cells (Tregs) regulate the functions of osteoclasts and osteoblasts, thus playing...